



SymBio Pharmaceuticals Limited
San-Ei Building, 5-23-7 Shimbashi, Minato-ku, Tokyo 105-0004, Japan
Tel: +81-3-5472-1125 Fax: +81-3-5472-3054 <http://www.symbiopharma.com/>

August 17, 2010

SymBio Pharmaceuticals Limited

Fuminori Yoshida

Representative Director

President and Chief Executive Officer

Dr. Albert Qin Joins SymBio as Medical Director

TOKYO, Japan, August 17, 2010 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, "SymBio,") is pleased to announce that Dr. Albert Qin has joined the company as Medical Director, Research and Development. Dr. Qin brings more than 16 years of experience in drug research and development in both the biotech and pharmaceutical industry to SymBio, and will strengthen the company's capabilities in drug development and its delivery of products to market as it continues to expand business activities in Asia Pacific. Prior to joining SymBio Pharmaceuticals, Dr. Qin served as Medical Director at ImmunoGen, Inc., and previously worked as Associate Director of Clinical Oncology at Pfizer, Inc., where he was responsible for running clinical oncology studies and actively involved in the clinical development of anticancer compounds. He spent the early part of his bio-pharmaceutical career focusing on anticancer research and pharmacology at Biogen, Inc., and Bayer Pharmaceuticals.

Dr. Qin earned his medical degree from the Department of Medicine at Shandong Medical University, and received his Ph.D. degree in Biochemistry and Molecular Pharmacology from Harvard University. Dr. Qin's extensive and wide-ranging experience in the research and development process of oncology products will be a tremendous asset as the company continues to build its presence in key Asia Pacific markets. Well-versed in the medical affairs of European and American drug development, Dr. Qin will enable SymBio to accelerate its efforts in bringing much-needed drugs to patients throughout the Asia Pacific region.

[Company Profile]

SymBio Pharmaceuticals Ltd. was established in March, 2005 by Fuminori Yoshida, who previously served concurrently as Corporate VP of Amgen Ltd. and President of Amgen Japan (currently Takeda Bio Development Center Limited). The company's underlying corporate mission is "delivering hope to patients in need" as it aspires to be a leading specialty pharmaceutical company in Asia Pacific dedicated to addressing underserved medical needs in the areas of oncology, hematology and autoimmune disease.

[Contact]

SymBio Pharmaceuticals Limited.

Motoji Horiguchi

Director, Human Resources & General Affairs

Tel: +081(0)3 5472 1125

URL: <http://www.symbiopharma.com>